# Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

> **NCT04162600** · PHASE1 · TERMINATED · sponsor: **University of Oxford** · enrollment: 18 (actual)

## Conditions studied

- Rabies

## Interventions

- **BIOLOGICAL:** ChAdOx2 RabG
- **BIOLOGICAL:** Inactivated Rabies Vaccine
- **BIOLOGICAL:** ChAdOx2 RabG
- **BIOLOGICAL:** ChAdOx2 RabG
- **BIOLOGICAL:** Inactivated Rabies Vaccine
- **BIOLOGICAL:** Inactivated Rabies Vaccine

## Key facts

- **NCT ID:** NCT04162600
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-02
- **Primary completion:** 2024-07-10
- **Final completion:** 2024-07-10
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Since acceptable safety, tolerability, and immunogenicity was demonstrated at the highest dose tested (group 3, fully recruited), there was no scientific or ethical justification to recruit more participants into the mid-dose group (group 2).
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162600, "Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04162600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*